“`html
Tandem Diabetes Care, Inc. (TNDM) reported a second-quarter 2025 loss of 48 cents per share, missing the Zacks Consensus Estimate of a 40-cent loss. On a GAAP basis, the loss widened to 78 cents per share from 47 cents a year earlier. Following the announcement, TNDM’s stock dropped by 20% on the subsequent Thursday.
For the quarter, non-GAAP revenues reached $240.7 million, marking an 8.5% increase year over year and surpassing estimates by 0.9%. The U.S. market contributed $170.2 million in sales (up 9% year-over-year), while international sales were $70.5 million, up from $65.2 million in the prior year. Gross profit improved to $125.9 million, and the gross margin increased to 52.3% despite rising costs.
Tandem expects full-year 2025 GAAP sales of approximately $1.00 billion, with U.S. sales projected at $700 million and international sales at $300 million, aligning with analysts’ estimates.
“`
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
